

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Mediwelcome Healthcare Management & Technology Inc. **麥迪衛康健康醫療管理科技股份有限公司**

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2159)

COMPLETION ANNOUNCEMENT IN RELATION TO THE PLACING OF NEW SHARES UNDER SPECIFIC MANDATE

References are made to (i) the announcements of Mediwelcome Healthcare Management & Technology Inc. (the “**Company**”) dated 30 March 2026, 5 May 2026, 28 May 2026, 26 June 2026, and 31 July 2026 (the “**Announcements**”); and (ii) the circular of the Company dated 8 May 2026 (the “**Circular**”) in relation to, among other things, the Acquisition and the Placing. Unless otherwise defined, capitalised terms used herein have the same meanings as defined in the Announcements and the Circular.

COMPLETION OF THE PLACING

The Board is pleased to announce that all the conditions set out in the Placing Agreement (as amended and supplemented from time to time) had been fulfilled and the Placing Completion took place on 31 August 2026. An aggregate of 56,480,000 Placing Shares have been placed to not less than six Placees at the Placing Price of HK\$1.50 per Placing Share pursuant to the terms and conditions of the Placing Agreement (as amended and supplemented from time to time), representing approximately 20.17% of the total issued share capital of the Company immediately before the Placing Completion and approximately 16.79% of the total issued share capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately after the Placing Completion.

The gross proceeds from the Placing is HK\$84.72 million, and the net proceeds from the Placing (after deduction of the placing commission and other related costs and expenses) are approximately HK\$79.99 million, representing a net issue price of approximately HK\$1.42 per Placing Share. The Company intends that the net proceeds from the Placing will be fully applied towards the cash payment of the Consideration.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, the Placees are professional, institutional or other investors who and whose respective ultimate beneficial owners are third parties independent of and not connected with the Company and its connected persons.

SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structure of the Company immediately before and after Placing Completion are as follows:

Shareholders	Immediately before Placing Completion		Immediately after Placing Completion	
	<i>Number of Shares</i>	<i>Approximate %</i>	<i>Number of Shares</i>	<i>Approximate %</i>
Ji Ze Investment Management Company Limited (<i>Note 1</i>)	40,651,000	14.52%	40,651,000	12.08%
Shun Jia Investment Management Company Limited (<i>Note 2</i>)	25,415,000	9.08%	25,415,000	7.55%
Tai Zhi Feng Investment Management Company Limited (<i>Note 3</i>)	12,038,000	4.30%	12,038,000	3.58%
He Hui Wan Yi Investment Management Company Limited (<i>Note 4</i>)	<u>25,415,000</u>	<u>9.08%</u>	<u>25,415,000</u>	<u>7.55%</u>
Sub-total (<i>Note 5</i>)	<u>103,519,000</u>	<u>36.98%</u>	<u>103,519,000</u>	<u>30.77%</u>
Mr. Shi Wei (<i>Note 1</i>)	1,950,000	0.69%	1,950,000	0.58%
Mr. Wang Liang (<i>Note 3</i>)	<u>1,800,000</u>	<u>0.64%</u>	<u>1,800,000</u>	<u>0.53%</u>
Sub-total (<i>Note 5</i>)	<u>107,269,000</u>	<u>38.31%</u>	<u>107,269,000</u>	<u>31.88%</u>
Deep Blue Fund SPC – Apollo SP (<i>Note 6</i>)	40,480,000	14.46%	40,480,000	12.03%
Public Shareholders				
Placees	–	–	56,480,000	16.79%
Other public Shareholders	<u>132,251,000</u>	<u>47.23%</u>	<u>132,251,000</u>	<u>39.30%</u>
	<u>280,000,000</u>	<u>100.00%</u>	<u>336,480,000</u>	<u>100.00%</u>

Notes:

1. *Ji Ze Investment Management Company Limited is wholly-owned by Mr. Shi Wei.*
2. *Shun Jia Investment Management Company Limited is wholly-owned by Mr. Yang Weimin.*
3. *Tai Zhi Feng Investment Management Company Limited, is wholly-owned by Mr. Wang Liang.*
4. *He Hui Wan Yi Investment Management Company Limited is wholly-owned by Ms. Zhang Yitao.*
5. *The Company's ultimate controlling shareholders, Mr. Shi Wei, Mr. Yang Weimin, Ms. Zhang Yitao and Mr. Wang Liang, are parties acting in concert. On 13 October 2019, they entered into written agreement to, among others, confirm their acting-in-concert arrangement. By virtue of the SFO, each controlling shareholder is deemed to be interested in the Shares beneficially owned by other controlling shareholders including the controlling shareholders' interest set out in notes 1 to 4 above.*
6. *Deep Blue Fund SPC – Apollo SP, is a segregated portfolio of Deep Blue Fund SPC. Deep Blue Fund SPC is a segregated portfolio company incorporated in the Cayman Islands operating as a private investment fund. Hong Kong International Capital Management Limited, a corporation licensed under the SFO permitted to engage in Type 4 (advising on securities), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities, is appointed as the investment manager of Deep Blue Fund SPC– Apollo SP. Hong Kong International Capital Management Limited is wholly owned by Hong Kong Financial Services Holding Limited.*

By order of the Board
Mediwelcome Healthcare Management & Technology Inc.
Shi Wei
Chairman and Executive Director

Hong Kong, 31 August 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Shi Wei, Mr. Yang Weimin, Mr. Wang Liang and Ms. Deng Chengying; one non-executive Director, namely Mr. Liu Xia; and three independent non-executive Directors, namely Mr. Song Ruilin, Mr. David Zheng Wang and Mr. Chen Huilin.